Physician profile
Sarah Bou Malham
NPI 1720392590
$548.62
in general payments reported to CMS, 2019-2025
17 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.18 · 2024: $175 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $91.93 | 2024-2025 | Minimed 780g, Inceptiv, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $66.33 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.87 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $49.11 | 2024-2025 | |
| Mannkind Corporation | $42.33 | 2024-2025 | |
| Insulet Corporation | $40.64 | 2025 | Omnipod |
| Abbott Laboratories | $35.28 | 2024-2025 | Freestyle Libre 3 |
| Alexion Pharmaceuticals, INC. | $23.99 | 2024 | Strensiq |
| Recordati_rare_diseases_inc. | $19.84 | 2025 | Isturisa |
| Pfizer INC. | $18.46 | 2025 | |
| Ionis Pharmaceuticals, INC. | $17.27 | 2025 | Tryngolza |
| Beta Bionics, INC. | $17.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $16.55 | 2025 | Twiist |
| Lexicon Pharmaceuticals, INC. | $15.30 | 2024 | |
| Esperion Therapeutics, INC. | $14.32 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $14.19 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bou Malham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.